Chiltern taps oncology expertise with Ockham acquisition

By Zachary Brennan

- Last updated on GMT

The acquisition will grow Chiltern's presence in the US.
The acquisition will grow Chiltern's presence in the US.

Related tags: Medicine, Chiltern

UK-based CRO Chiltern has agreed to acquire Ockham, a North Carolina-based full-service CRO, and the combined company will now compete with mid-sized CROs. Financial terms of the acquisition were not announced.

The combined company, which will retain the name Chiltern, will keep Chiltern’s CEO Jim Esinhart as CEO, while Ockham’s CEO James Baker will become Chief Development Officer.

Esinhart said: “This merger is a natural progression towards our strategic goal of becoming the premier specialized mid-tier CRO. Throughout this process I have been extremely impressed by the skill and professionalism of Ockham’s employees, the quality services they deliver, and the vision of the leadership team.​”

The acquisition comes as Chiltern saw increasing amounts of growth​ of the past few years in the US and central and eastern Europe and this acquisition will clearly increase the company’s presence in the US. It also follows the company’s consolidation of ownership back in December after private equity investor Kester Capital sold its stake in the CRO​, which also has operations in India, Taiwan, Australia and Singapore.

The goal of the transaction is to strengthen the companies’ combined service offerings in three areas:

• Oncology specialization, with expertise across all clinical phases of development. In 2012, Ockham purchased oncology specialist Nexus​, which bolstered its offering in this specialty;

• Biopharmaceutical services with global reach and scale, including therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology; and

• Global Functional Service Provider (FSP)/Sourcing provision specializing in tailored resourcing solutions across clinical, regulatory, medical and biometrics.

Baker added: “In Ockham’s continuing progression toward building the top niche oncology CRO, our joining with Chiltern has been an easy choice, allowing us to leverage Chiltern’s global reach and highly developed staffing business in Europe, both of which are complementary to Ockham’s deep oncology expertise and source business in the US. We are fortunate to have found the ideal partner with a complete understanding and commitment to the unique needs of our emerging biotech clientele​.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars